Epidemiological and Clinical Data in Low and Intermediate Risk Neuroblastoma: A Single Institution Experience and Survival Outcomes in Jerusalem

Authors

  • Ala H Sbeih Doctor of medicine
  • Khadra Salami
  • Fortunato Morabito
  • Hani Saleh

DOI:

https://doi.org/10.31557/apjcc.2020.5.3.139-144

Keywords:

Neuroblastoma, risk stratification, survival.

Abstract

Objective: The aim of this study is to evaluate survival outcomes in neuroblastoma patients referred to Augusta Victoria hospital, Jerusalem between 2009 and 2018.
Methods: This is a retrospective study of clinical and epidemiological data evaluating 34 low and intermediate risk neuroblastoma patients treated at a paediatric hematology/oncology center. Information of demographic, treatment modalities, and survival outcome were abstracted from patients medical records.
Results: Diagnosing neuroblastoma is challenging due to its wide range of signs and symptoms. In this study, 34 patients were included, with a male to female ratio of 1:26 :1.0. The most common location of the tumor is the abdomen followed by the mediastinal region. Forthy one percent of the cases presented with metastasis, mainly to the liver (20%), bone marrow (15%), and the lymph nodes (6%). Overall survival for Low risk neuroblastoma is 100% while the Intermediate risk neuroblastoma had a 93.1% chance of survival.
Conclusion: The outcome and prognosis of low risk and intermediate risk Neuroblastoma is excellent as it is seen in developed countries. More attention is needed for early detection and early treatment could improve survival.

Published

2020-08-15

How to Cite

Sbeih, A. H., Salami, K., Morabito, F., & Saleh, H. (2020). Epidemiological and Clinical Data in Low and Intermediate Risk Neuroblastoma: A Single Institution Experience and Survival Outcomes in Jerusalem. Asian Pacific Journal of Cancer Care, 5(3), 139–144. https://doi.org/10.31557/apjcc.2020.5.3.139-144

Issue

Section

Original Research